3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urologic Diseases
2
Urinary Bladder Neoplasms
2
Urinary Bladder Diseases
2
Carcinoma, Transitional Cell
2
Interventions
Gemcitabine
47
Cisplatin
32
pembrolizumab
28
Paclitaxel
13
Docetaxel
13
avelumab
12
Mitomycin
12
atezolizumab
11
Nivolumab
11
Cystectomy
10
Carboplatin
9
durvalumab
7
Sunitinib
7
apaziquone
6
Doxorubicin
6
BCG Vaccine
6
5-aminolevulinic acid hexyl ester
6
Vinblastine
5
Radiation
5
Platinum
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Albumin-Bound Paclitaxel
5
Taxes
4
Standard of Care
4
Sorafenib
4
Radiotherapy
4
Fluorouracil
4
Erlotinib Hydrochloride
4
1,2-diaminocyclohexaneplatinum II citrate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Urinary Bladder Neoplasms
×
B701 protein, Human herpesvirus 6
×
Clear all
NCT03123055
2020-03-18
FIERCE-22
Rainier Therapeutics
Phase 1/2
Terminated
28 enrolled
8 charts
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts